ClinicalTrials.gg

Program

CTX460

A development code.

Its studies are mostly in alpha 1-Antitrypsin Deficiency, led by CRISPR Therapeutics.

Furthest: phase 2, since Sep 21, 20261 company-led study, 1 open or runningNext primary completion: Jun 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CRISPR Therapeutics11 open or runningphase 2since Sep 21, 2026Sep 21, 2026Jun 2030phase 2 · NCT07850076

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 21, 2026First study: phase 2 study in alpha 1-Antitrypsin DeficiencyFirst studyNCT07850076 · 68 planned · Australia

Ahead

  1. Jun 2030Primary completion: phase 2 study in alpha 1-Antitrypsin DeficiencyNCT07850076

TargetBeta

SERPINA1 →read by rule
“Official Title: A Phase 1/2 Multicenter, Open-label, First-in-Human Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460, a Lipid Nanoparticle Formulation of SyNTase Editing Components for In Vivo Editing of the Serine Protease Inhibitor A1 (SERPIN…”study text, by rule · the study

Other programs on SERPINA1

ProgramCompanyFurthest phaseStudies
ensitrelvirruleShionogiphase 35
efdoralprin alfaSanofiphase 22
Proteasome Inhibitor SHY-ONC6ruleshy-therapeuticsphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07850076alpha 1-Antitrypsin Deficiency · Australia2RecruitingJun 203068

How it is read

Names in the registry

  • “CTX460”, 1 entry

Codes read as this program: CTX460.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.